{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(8)"],"submitter":["Yang Q"],"pubmed_abstract":["<b>Background:</b> Multiple myeloma (MM) is incurable in spite of recent treatment improvements, highlighting the development of new therapies. Chimeric antigen receptor (CAR) T-cell therapy has dramatically changed the therapeutic effectiveness in high-risk B-cell malignancies. For relapsed/refractory multiple myeloma (RRMM), preclinical evaluations of CAR-T therapy have shown promising efficacy, thus various active clinical trials are under way. Herein, we conducted this review to summarize efficacy and safety of CAR-T therapy and provide more evidence to guide clinical treatments. <b>Method:</b> We systematically searched literature based on databases (PubMed, EMBASE, Cochrane Central Register of Controlled Trials), and conference abstracts reported from American Society of Hematology ("],"journal":["International journal of medical sciences"],"pagination":["1786-1797"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7976586"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis."],"pmcid":["PMC7976586"],"pubmed_authors":["Li X","Zhang F","Liu J","Zhou W","Yang Q"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.","description":"<b>Background:</b> Multiple myeloma (MM) is incurable in spite of recent treatment improvements, highlighting the development of new therapies. Chimeric antigen receptor (CAR) T-cell therapy has dramatically changed the therapeutic effectiveness in high-risk B-cell malignancies. For relapsed/refractory multiple myeloma (RRMM), preclinical evaluations of CAR-T therapy have shown promising efficacy, thus various active clinical trials are under way. Herein, we conducted this review to summarize efficacy and safety of CAR-T therapy and provide more evidence to guide clinical treatments. <b>Method:</b> We systematically searched literature based on databases (PubMed, EMBASE, Cochrane Central Register of Controlled Trials), and conference abstracts reported from American Society of Hematology (","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-19T13:57:57.405Z","creation":"2025-04-19T13:57:57.405Z"},"accession":"S-EPMC7976586","cross_references":{"pubmed":["33746596"],"doi":["10.7150/ijms.46811"]}}